beta Amyloid Protein

Catalog No. ABIN7272125

This Synthetic beta Amyloid protein is produced in Synthetic.

Quick Overview for beta Amyloid Protein (ABIN7272125)

Target: beta Amyloid (Abeta) (Amyloid beta (Abeta))

Protein Type: Synthetic

Origin: Human

Source: Synthetic

Application: Western Blotting (WB), In vitro Assay (in vitro), In vivo Studies (in vivo)

Purity: >95% pure using mass spec and HPLC.

Product Details

Purpose: Human Synthetic Amyloid Beta Peptide 1-42 (HFIP treated) Monomers

Sequence: DAEFRHDSGY EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV IA

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Storage: -80 °C

Storage Comment: -80°C

Target Details

Target: beta Amyloid (Abeta) (Amyloid beta (Abeta))

Alternative Name: Amyloid Beta

Background: Our amyloid beta peptide 1-42 (Aβ42) is produced synthetically and treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) prior to drying which breaks down pre-formed fibrils and monomerizes the peptide, as previously published (1,2). Upon resuspension in DMSO/dH2O, our Aβ42 presents as a monomeric peptide without fibrils when observed under TEM, AFM and on a Western Blot with an anti-amyloid beta antibody. In contrast to AB42 oligomer and fibril constructs, our Aβ42 monomers were not toxic to primary rat cortical neurons. In the brain, amyloid beta peptide (Aβ) is generated by protease cleavage of amyloid precursor protein (APP), which aggregates into oligomers, protofibrils, fibrils and ultimately plaques in neurodegenerative diseases. The accumulation of Aβ plaques in the brain is considered a hallmark of Alzheimer's disease (AD), and most of the drugs tested for AD in the past 20 years have targeted amyloid beta accumulation (3). Soluble Aβ oligomers isolated from the brains of AD patients or those generated in vitro potently impaired synapse structure and function (4). Aβ oligomers generated in vitro were toxic to PC12 cells (2) and SH-SY5Y cells (5). Aβ was demonstrated to interact with tauopathies to affect neurodegeneration in AD patients (6) and accumulations of Aβ were shown to be associated with lower survival rates in Parkinson's disease patients with dementia (7)., cellular localisation: Cell Membrane , Intracellular Vesicles

Molecular Weight: 4.5 kDa

Gene ID: 351

UniProt: P05067

Pathways: Inflammasome